Celladon Corporation’s CLDN shares plummeted 80.7% following the company’s announcement that randomized, double-blind, placebo-controlled, multinational phase IIb study (CUPID2) on advanced heart ...

Celladon said yesterday its lead investigational product candidate, the cardiovascular gene therapy agent Mydicar® (AAV1/SERCA2a), did not meet its primary and secondary endpoints in the Phase IIb ...

SAN DIEGO, April 26, 2015 -- Celladon Corporation (CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, ...

In a report published Monday, Wedbush analysts downgraded Celladon Corp (NASDAQ: CLDN) from Outperform to Neutral. The price target has been lowered from $29 to $3. The company announced on Sunday ...

SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), today announced that its Board of Directors has unanimously approved a strategic plan pursuant to which the Company will ...

"We are surprised and very disappointed that MYDICAR failed to meet the endpoints in the CUPID2 trial, and we are rigorously analyzing the data in an attempt to better understand the observed outcome.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. On its website, Celladon Corp. (NASDAQ: CLDN) writes ...

Pompey, France, and San Diego, CA, USA, March 24, 2015 - Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation (Nasdaq:CLDN), ...

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company, ...